National Institutes of Health
Bethesda, MD
Accepting patients
Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
- Donor Lymphocyte Infusion (DLI)
- Post-Allogeneic Stem Cell Transplant
- Phase 1/2
Accepting patients
Collection of Biological Samples
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- Observational Trial
Accepting patients
Omidubicel (former CordIn)
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome
- Cord Blood
- Phase 1/2
Accepting patients
G-CSF Mobilized CD34+ Cells in Transplant
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells
- Allogeneic Stem Cell Transplant
- CD34
- Phase 2
Accepting patients
Safety Study of Cord Blood Units
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Post-Transplant Cyclophosphamide
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
- Allogeneic Stem Cell Transplant
- Chemotherapy
- Phase 2
Accepting patients
GATA2 Genetic Testing
The Natural History of GATA2 Deficiency and Related Disorders
- Genetic Sequencing
- Observational Trial
Accepting patients
Allo Stem Cell Transplant for GATA2 Mutations
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
JSP191-Based Conditioning
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
- Allogeneic Stem Cell Transplant
- Monoclonal Antibody
- Phase 2
Not yet accepting
Pacritinib
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- Kinase Inhibitor
- Phase 1/2